News Column

Studies from Gonda Vascular Center Have Provided New Information about Coagulation (Outcomes and total costs of outpatient vs. inpatient...

August 6, 2014



Studies from Gonda Vascular Center Have Provided New Information about Coagulation (Outcomes and total costs of outpatient vs. inpatient peri-procedural anticoagulation management of mechanical prosthetic heart valve patients)

By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Coagulation are presented in a new report. According to news reporting originating from Rochester, Minnesota, by NewsRx correspondents, research stated, "The most cost-effective periprocedural management of patients with mechanical heart valves (MHV) is uncertain. The objective was to compare the effectiveness, safety and costs for inpatient intravenous unfractionated heparin (IVUH) vs. outpatient low molecular weight heparin (LMWH) 'bridging' as periprocedural anticoagulation management for MHV patients."

Our news editors obtained a quote from the research from Gonda Vascular Center, "In a case-cohort study, Olmsted County, MN residents with MHV who received outpatient periprocedural LMWH management (cases) over the 11-year period, 1997-2007, were matched to residents with MHV who received inpatient IVUH periprocedural management on valve location and type, and on procedure type. Patients were followed for 3 months following hospitalization to identify thromboembolism (TE) and major bleeding. Total costs from 30 days before to 90 days after the procedure were determined from the Olmsted County Healthcare Expenditure and Utilization Database. Outcomes were compared using survival analysis and costs were compared using the Wilcoxon rank sum. 149 cases (100 aortic, 29 mitral, 20 both; 64% bileaflet) were compared to 149 cohort members (100 aortic, 29 mitral, 20 both; 75% bileaflet). While the 3-month cumulative incidence of TE did not differ significantly among cases (2.7%) and cohort members (4.7%; p=0.36), major bleeding was significantly lower in cases (5.4% vs. 15.4%; p$50,984 vs. $39,347; p=0.002) due to higher inpatient costs ($47,729 vs. $34,860; p=0.0002)."

According to the news editors, the research concluded: "Outpatient bridging LMWH therapy is equally effective, but safer and less costly than inpatient IVUH as periprocedural anticoagulation management for MHV patients."

For more information on this research see: Outcomes and total costs of outpatient vs. inpatient peri-procedural anticoagulation management of mechanical prosthetic heart valve patients. International Journal of Cardiology, 2013;168(6):5311-5. (Elsevier - www.elsevier.com; International Journal of Cardiology - www.elsevier.com/wps/product/cws_home/506041)

The news editors report that additional information may be obtained by contacting H. Attaya, Mayo Clinic Thrombophilia Center, Gonda Vascular Center, Mayo Clinic, Rochester, MN, United States. Additional authors for this research include N.D. Shah, W.E. Wysokinski, H.K. Van Houten, J.A. Heit and R.D McBane (see also Coagulation).

Keywords for this news article include: Therapy, Rochester, Minnesota, Hematology, Coagulation, United States, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters